Compass Pathways falls; fast-track review of depression drug blocked, reports say

COMPASS Pathways

04/02/2026 17:46

Updates

** Shares of drug developer Compass Pathways CMPS.O fall 6% to $6.20

** STAT News reports Trump administration officials vetoed the Food and Drug Administration's plan to fast-track the review of co's psychedelic treatment for severe depression

** The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants

** Co had previously said it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months after a positive meeting with FDA

** "For Compass, given our Breakthrough Designation and potential for rolling submission and review, we do not expect the voucher would dramatically alter our timeline" - CMPS said in an emailed response

** "We continue to have an excellent relationship with the psychiatry division of the FDA and we expect to be able to work with them on a potential rolling submission and review of our NDA" - CMPS

** Reuters could not immediately verify the report

** Stock was up 82.5% in 2025

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com))